Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 4/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071544 | 0.84 | TSHR (0.46) | CYP2C19ALDH1A1KDM4ETSHRL3MBTL1 | |
| SCHEMBL8636775 | 0.84 | CNR1 (0.55) | CYP2A13CNR1CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL2189009 | 0.75 | HSP90AA1 (0.48) | CYP2A13CNR1ALDH1A1KDM4ETSHR | |
| SCHEMBL4631793 | 0.74 | KDM4E (0.54) | CYP3A4CYP2C19ALDH1A1KDM4ETSHR | |
| SCHEMBL27903062 | 0.72 | ALDH1A1 (0.46) | CYP2A13CYP2C19ALDH1A1KDM4ETSHR | |
| SCHEMBL3311657 | 0.70 | CYP2A13 (1.00) | CYP2A13ALDH1A1KDM4EMGLL | |
| SCHEMBL4097834 | 0.68 | CYP2A13 (1.00) | CYP2A13ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4105446 | 0.68 | KCNH2 (0.74) | CYP2A13CNR1MGLL | |
| SCHEMBL4703881 | 0.68 | CYP2A13 (0.51) | CYP2A13CNR1ALDH1A1KDM4ETSHR | |
| SCHEMBL4960631 | 0.67 | CYP19A1 (0.42) | CYP3A4CYP2C19ALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | CYP2A13 3079/4885CNR1 181/4885CYP3A4 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.